S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
NASDAQ:ERAS

Erasca (ERAS) Stock Price, News & Analysis

$2.38
+0.03 (+1.28%)
(As of 02/29/2024 ET)
Today's Range
$2.33
$2.50
50-Day Range
$1.67
$2.46
52-Week Range
$1.51
$3.70
Volume
2.57 million shs
Average Volume
864,203 shs
Market Capitalization
$359.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Erasca MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
236.1% Upside
$8.00 Price Target
Short Interest
Bearish
11.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of Erasca in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$1.29 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.95) to ($1.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.67 out of 5 stars

Medical Sector

503rd out of 958 stocks

Pharmaceutical Preparations Industry

243rd out of 448 stocks


ERAS stock logo

About Erasca Stock (NASDAQ:ERAS)

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

ERAS Stock Price History

ERAS Stock News Headlines

ERAS Mar 2024 2.000 put
Erasca (NASDAQ:ERAS) Trading 3.1% Higher
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
ERAS Mar 2024 2.500 call
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Erasca Co-Founder Acquires 3.2% More Stock
Erasca GAAP EPS of -$0.20 beats by $0.01
Erasca Inc ERAS
Insider Spends US$2.0m Buying More Shares In Erasca
See More Headlines
Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
2/29/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ERAS
Fax
N/A
Employees
129
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$11.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+250.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-242,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.37 per share

Miscellaneous

Free Float
106,063,000
Market Cap
$344.49 million
Optionable
Optionable
Beta
0.90
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Jonathan E. Lim M.D. (Age 52)
    Co-Founder, Chairman & CEO
    Comp: $940.32k
  • Dr. David M. Chacko M.D. (Age 40)
    CFO & Chief Business Officer
    Comp: $616.76k
  • Dr. Michael D. Varney Ph.D. (Age 66)
    Chairman of Research & Development, Scientific Advisory Board Member and Director
    Comp: $83.26k
  • Dr. Nik Chetwyn Ph.D.
    Chief Operating Officer
  • Mr. Ebun S. Garner J.D. (Age 52)
    Esq., General Counsel & Corporate Secretary
    Comp: $510.98k
  • Dr. Lisa Tesvich-Bonora Ph.D.
    Chief People Officer
  • Mr. Brian L. Baker CPA (Age 57)
    M.S., Senior Vice President of Finance
  • Ms. Chandra D. Lovejoy M.S. (Age 53)
    Chief Regulatory Affairs Officer
  • Dr. Robert Shoemaker Ph.D. (Age 43)
    Senior Vice President of Research
  • Dr. Shannon R. Morris M.D. (Age 54)
    Ph.D., Chief Medical Officer














ERAS Stock Analysis - Frequently Asked Questions

Should I buy or sell Erasca stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Erasca in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ERAS shares.
View ERAS analyst ratings
or view top-rated stocks.

What is Erasca's stock price target for 2024?

3 brokerages have issued 12-month price objectives for Erasca's stock. Their ERAS share price targets range from $6.00 to $11.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 236.1% from the stock's current price.
View analysts price targets for ERAS
or view top-rated stocks among Wall Street analysts.

How have ERAS shares performed in 2024?

Erasca's stock was trading at $2.13 on January 1st, 2024. Since then, ERAS stock has increased by 11.7% and is now trading at $2.38.
View the best growth stocks for 2024 here
.

When is Erasca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our ERAS earnings forecast
.

How were Erasca's earnings last quarter?

Erasca, Inc. (NASDAQ:ERAS) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.05.

What ETF holds Erasca's stock ?

Virtus LifeSci Biotech Clinical Trials ETF holds 40,125 shares of ERAS stock, representing 0.90% of its portfolio.

When did Erasca IPO?

(ERAS) raised $262 million in an initial public offering on Thursday, July 15th 2021. The company issued 17,500,000 shares at a price of $14.00-$16.00 per share.

Who are Erasca's major shareholders?

Erasca's stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (5.36%), Vanguard Group Inc. (2.51%), PFM Health Sciences LP (1.70%), Schroder Investment Management Group (1.27%), Goldman Sachs Group Inc. (0.86%) and Northern Trust Corp (0.46%). Insiders that own company stock include Alexander W Casdin, Bihua Chen, Jonathan E Lim and Valerie Denise Harding Start.
View institutional ownership trends
.

How do I buy shares of Erasca?

Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ERAS) was last updated on 2/29/2024 by MarketBeat.com Staff